medicalxpress.com
Physician–researcher's work yields landmark five-year data for Crohn's disease drug
Long-term (five-year) data suggest guselkumab may provide sustained clinical and endoscopic benefit for people with moderate-to-severe Crohn’s disease, which is important for disease control and reducing need for surgery. Safety signals were reportedly consistent over five years.
Adults with Crohn’s disease, patients on or considering biologic/IL-23 therapies, gastroenterologists, and IBD researchers.
What To Know
Five-year long-term-extension results for guselkumab (an IL-23 p19 inhibitor, brand name Tremfya) in moderately to severely active Crohn’s disease are reported from the Phase 2 GALAXI 1 program and summarized here.
The article highlights sustained clinical remission, endoscopic response and endoscopic remission rates among patients remaining on therapy over five years, and notes no new safety signals. The work is led by Anita Afzali and published in Inflammatory Bowel Diseases; GALAXI program trials were funded by Johnson & Johnson.
This news item reports long-term follow-up data (five years) from a clinical development program for guselkumab in Crohn’s disease. The key points are sustained clinical and endoscopic benefit among patients who stayed on treatment and a consistent safety profile over the follow-up period.
The article cites objective measures such as endoscopic response and remission and places these findings in the context of prior GALAXI induction, maintenance, and Phase 3 publications.
It does not provide detailed methods, full numerical denominators, nor independent expert critique; the findings come from the trial program funded by the drug manufacturer and reported in a peer-reviewed journal.
For individual treatment decisions or interpretation of applicability, patients should discuss with their care team and consult the original Inflammatory Bowel Diseases paper for full data.
Adults with Crohn’s disease, especially those considering or currently on biologic/IL-23 therapies; clinicians treating moderate-to-severe Crohn’s; researchers in IBD therapeutics and translational gastroenterology. These are long-term extension results from a clinical development program and represent promising durability
This summary is based on a MedicalXpress report of a five-year analysis published in Inflammatory Bowel Diseases. The article highlights outcomes for patients who remained on therapy; it does not give full trial methods, enrollment numbers, or subgroup details. The GALAXI program was sponsored by Johnson & Johnson; consult the original paper for complete data and context.
